Last reviewed · How we verify
NCT06679647
Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong
NA trial testing Access to a trained ChatGPT in Behavior Change Interventions in 50 participants. Not yet recruiting.
31 March 2025
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 50 |
| Start date | 1 December 2024 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
Drugs / interventions tested
- Access to a trained ChatGPT
Conditions studied
- Behavior Change Interventions — all drugs for Behavior Change Interventions →
Sponsor
Chinese University of Hong Kong
Who can join
65 and older, any sex, with Behavior Change Interventions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong. This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong. The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1). The secondary objectives are to evaluate the following conditions measured at T1, as compared to those measured at baseline (T0): 1. Self-reported uptake of SIV in the past month. 2. Changes in behavioural intention to receive SIV for the approaching flu season. 3. Changes in knowledge and attitudes related to SIV.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study.
Wang Z, Tsang TH, Yu FY, Fang Y, et al · · 2025 · cited 1× · PMID 40921067 · DOI 10.2196/76849
Verify or expand the search:
- PubMed search for NCT06679647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Behavior Change Interventions
Currently open trials in the same condition.
- NCT07417254 — Novel Personalised Nutrition Intervention With Tailored Behavioural Support · NA · recruiting
- NCT06852443 — Troubled-Desire & Therapeutic Chat for Reduction of CSAM Use (TD-CHAT) · NA · recruiting
- NCT07299201 — Proactive Telemedicine to Improve Healthcare Access and Prevention in Rural Primary Care (PTM) · NA · active not recruiting
- NCT06359210 — Sustaining Physical Activity After Cancer Exercise Sessions · NA · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06679647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06679647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing